Solera Health, an integrated benefit network, and WellDoc, a leading digital therapeutic company has announced that WellDoc’s BlueStar® digital therapeutic will join the Solera network as a diabetes management solution of choice. The integration partnership aligns both companies’ goals to improve the lives of those living with chronic diseases while enhancing clinical results and decreasing overall healthcare costs.Solera Health connects patients, payers and physicians with community
Read More
WellDoc
WellDoc, AADE Jointly Launch The Diabetes Digital Health Learning Network
WellDoc, a digital health company revolutionizing chronic disease management to help transform lives has announced the launch of ‘The Diabetes Digital Health Learning Network’ in collaboration with the American Association of Diabetes Educators (AADE). The Learning Network will support its members who are on the front lines of diabetes care and management by assisting diabetes educators in gaining next-generation skills in using digital health therapeutics to improve clinical care and outcomes
Read More
WellDoc Founders Launch FDA-Cleared Mobile Insulin Titration App for Diabetes Management
The team that created the first FDA-cleared mobile app for diabetes management at WellDoc has launched a completely new digital health company, Amalgam Rx. The new company is focused on developing next-generation, evidence-based digital therapies that empower and engage patients with chronic diseases. Amalgam’s first product, iSage Rx is the first FDA 510(k)-cleared, prescription-only, mobile insulin titration app of all brands of basal insulin including Lantus, Levemir, Toujeo, Tresiba and
Read More
Samsung Health Integrates with WellDoc’s Consumer Diabetes Health App
Today, WellDoc announced it has entered a joint commercial partnership agreement with Samsung. The enhanced partnership with WellDoc gives Samsung an opportunity to serve global consumers who are ready to embrace the combined health innovations that both companies plan to offer. Samsung also becomes a distribution channel for WellDoc.The companies will integrate WellDoc’s newly-released consumer diabetes health app, BlueStar® C, with the recently launched Samsung Health, a mobile one-stop shop
Read More
WellDoc Receives FDA 510(k) Clearance for Non-Prescription Version of BlueStar® Digital Therapeutic
Digital health leader WellDoc has received FDA 510(k) class II clearance for a non-prescription version of the BlueStar® digital therapeutic diabetes management platform. This news comes on the heels of two other significant recent announcements for BlueStar®: the FDA’s clearance of the wireless integration of LifeScan’s OneTouch Verio Flex® blood glucose monitoring system with BlueStar®, and plans to incorporate the American Association of Diabetes Educators’ (AADE) curriculum in the BlueStar®
Read More
WellDoc, American Association of Diabetes Educators Partner on Digital Diabetes Content
WellDoc and the American Association of Diabetes Educators (AADE) has partnered to integrate its “AADE Diabetes Education Curriculum: A Guide to Successful Self-Management” into WellDoc's BlueStar digital therapeutic platform. BlueStar is an FDA-cleared digital therapeutic used to help adults living with type 2 diabetes self-manage their condition. Additionally, both parties will explore how to collectively engage AADE’s members, as well as develop new strategies that bring innovative tools to
Read More
WellDoc, LifeScan Integrate to Create Type 2 Diabetes Management Platform
WellDoc has entered a commercial partnership agreement with LifeScan Inc., a Johnson & Johnson Diabetes Care Company (JJDCC), to deliver a best-in-class digital health solution for individuals living with Type 2 diabetes. The combined offering will seek to create a comprehensive, data-driven and payer-reimbursed program for Type 2 diabetes management.WellDoc’s BlueStar® diabetes management platform and mobile app is the first digital therapeutic approved by the U.S. Food and Drug
Read More
WellDoc, Human API Partner To Integrate Type 2 Diabetes Patient Data
Digital health technology company WellDoc has announced a partnership with health data platform Human API to integrate type 2 diabetes patient health data within WellDoc’s BlueStar digital therapeutic. As part of the collaboration, Human API’s data platform will provide WellDoc with real-time access to comprehensive clinical patient data from its network of 15,000+ pharmacies, health systems and laboratories. The steady flow of data is shared within a highly secure environment that ensures
Read More
WellDoc, Lifespan Partner to Deliver Diabetes-Focused Digital Health Solution
WellDoc, a digital health technology leader, today announced a collaboration with LifeScan, Inc., a business within the Johnson & Johnson Diabetes Care Companies to deliver a best-in-class digital health solution for patients living with Type 2 diabetes. Under the collaboration, WellDoc’s BlueStar product, the first FDA-cleared digital therapeutic for adults who live with Type 2 diabetes, will be integrated with LifeScan’s OneTouch Verio Flex™ Bluetooth® Smart blood glucose monitoring
Read More
WellDoc Pulls In $22M To Accelerate Mobile Prescription Therapy Adoption
Digital health technology company WellDoc today announced $22 million in Series B funding led by Samsung Ventures and Merck Global Health Innovation (GHI) Fund serving as co-lead. Other participants in the round include Adage Capital Management, Excel Venture Management, Alexandria Venture Investments and Hudson River Capital Partners LLC. Welldoc plans to utilize the funding to continue commercialization and accelerate adoption of its flagship product, BlueStar, a FDA cleared mobile
Read More
